Login to Your Account



Clinic Roundup


Wednesday, February 16, 2011
Alkermes Inc., of Waltham, Mass., reported that its candidate for opioid induced bowel dysfunction (OBD), ALKS 37, significantly improved GI motility and increased frequency of bowel movements in a Phase II trial. The trial enrolled 87 patients with OBD who were randomized to receive escalating doses of ALKS 37, with the two highest doses showing the positive effects. The drug will be moved into a pivotal program in mid-2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription